Skip to main content

Table 4 Relative risks of progression within 24 months and overall death within 5 years according to clinicopathological factors and RBM3 expression in patients with Ta and T1 tumours

From: Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer

   Risk of progression within 24 months    Risk of death within 5 years
   Univariable Multivariable    Univariable Multivariable
  n(events) HR(95%CI) HR(95%CI)   n(events) HR(95%CI) HR(95%CI)
Age        
Continuous 134(19) 1.02(0.98-1.07) 1.01(0.97-1.06)   231(88) 1.06(1.04-1.09) 1.06(1.04-1.08)
Gender        
Female 29(2) 1.00 1.00   43(12) 1.00 1.00
Male 105(17) 2.48(0.57-10.74) 1.98(0.45-8.64)   188(76) 0.62(0.34-1.13) 1.67(0.90-3.10)
Grade        
Low 48(3) 1.00 1.00   81(19) 1.00 1.00
High 86(16) 3.24(0.94-11.12) 3.32(0.97-11.40)   150(69) 2.22(1.33-3.68) 1.31(0.73-2.35)
Stage        
Ta 68(7) 1.00 1.00   115(35) 1.00 1.00
T1 66(12) 1.90(0.75-4.83) 1.24(0.44-3.46)   116(53) 0.61(0.40-0.93) 1.61(1.04-2.49)
RBM3 expression*     RBM3 expression*    
High 31(1) 1.00 1.00 Positive 198(69) 1.00 1.00
Negative/Intermediate 103(18) 5.92(0.79-44.39) 6.10(0.81-45.69) Negative 33(19) 2.00(1.21-3.33) 1.64(0.96-2.78)
  1. For PFS a dichotomised variable comparing patients with negative or intermediate RBM3 expression to those with high expression was applied. For 5 year OS, a dichotomised variable of negative versus any RBM3 expression was applied.